Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
about
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): The DERIVE Study
description
im November 2018 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 10 July 2018
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2018
@uk
name
Efficacy and safety of dapagli ...... se stage 3A): The DERIVE Study
@en
Efficacy and safety of dapagli ...... and moderate renal impairment
@nl
type
label
Efficacy and safety of dapagli ...... se stage 3A): The DERIVE Study
@en
Efficacy and safety of dapagli ...... and moderate renal impairment
@nl
prefLabel
Efficacy and safety of dapagli ...... se stage 3A): The DERIVE Study
@en
Efficacy and safety of dapagli ...... and moderate renal impairment
@nl
P2093
P2860
P50
P356
P1476
Efficacy and safety of dapagli ...... se stage 3A): The DERIVE Study
@en
P2093
Anna Maria Langkilde
C David Sjöström
DERIVE Study Investigators
Daniel Reyner
John B Buse
Peter Sartipy
Ronald Goldenberg
P2860
P304
P356
10.1111/DOM.13413
P407
P577
2018-07-10T00:00:00Z